These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17004113)

  • 1. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
    Olson JE; Ingle JN; Ma CX; Pelleymounter LL; Schaid DJ; Pankratz VS; Vierkant RA; Fredericksen ZS; Wu Y; Couch FJ; Vachon CM; Sellers TA; Weinshilboum RM
    Breast Cancer Res Treat; 2007 Apr; 102(2):237-47. PubMed ID: 17004113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
    Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
    Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
    Talbott KE; Gammon MD; Kibriya MG; Chen Y; Teitelbaum SL; Long CM; Gurvich I; Santella RM; Ahsan H
    Breast Cancer Res Treat; 2008 Oct; 111(3):481-7. PubMed ID: 17975727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP19 (aromatase) haplotypes and endometrial cancer risk.
    Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I
    Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
    Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
    In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
    Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
    Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
    Han DF; Zhou X; Hu MB; Xie W; Mao ZF; Chen DE; Liu F; Zheng F
    Chin Med J (Engl); 2005 Sep; 118(18):1507-16. PubMed ID: 16232327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
    Cai Q; Kataoka N; Li C; Wen W; Smith JR; Gao YT; Shu XO; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):27-32. PubMed ID: 18199708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
    Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
    Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
    Straume AH; Knappskog S; Lønning PE
    J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):69-75. PubMed ID: 21939764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.
    Zhang L; Gu L; Qian B; Hao X; Zhang W; Wei Q; Chen K
    Breast Cancer Res Treat; 2009 Mar; 114(2):327-38. PubMed ID: 18629629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms and haplotype of hormone-related genes are associated with the risk of breast cancer in Chinese women.
    Pan Z; Fu Z; Song Q; Cao W; Cheng W; Xu X
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between estrogen-biosynthesis gene (CYP17, CYP19, HSD17beta1) polymorphisms and breast cancer].
    Wang YP; Li H; Li JY; Yuan P; Yang F; Lei FM; Pang Y; Guo J
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):899-903. PubMed ID: 20193327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk.
    Gaudet MM; Chanock S; Lissowska J; Berndt SI; Peplonska B; Brinton LA; Welch R; Yeager M; Bardin-Mikolajczak A; Garcia-Closas M
    Cancer Res; 2006 Oct; 66(19):9781-5. PubMed ID: 17018638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.
    Kim JY; Lee CS; Kim HO; Jo YH; Lee J; Jung MH; Baik HH; Choe W; Kang I; Yoon KS
    Oncol Rep; 2009 Sep; 22(3):487-92. PubMed ID: 19639193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women].
    Hu MB; Xie W; Xiong B; Han DF; Li Y; Feng MH; Zhou YF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Apr; 27(4):351-5. PubMed ID: 16875543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies.
    Feigelson HS; Cox DG; Cann HM; Wacholder S; Kaaks R; Henderson BE; Albanes D; Altshuler D; Berglund G; Berrino F; Bingham S; Buring JE; Burtt NP; Calle EE; Chanock SJ; Clavel-Chapelon F; Colditz G; Diver WR; Freedman ML; Haiman CA; Hankinson SE; Hayes RB; Hirschhorn JN; Hunter D; Kolonel LN; Kraft P; LeMarchand L; Linseisen J; Modi W; Navarro C; Peeters PH; Pike MC; Riboli E; Setiawan VW; Stram DO; Thomas G; Thun MJ; Tjonneland A; Trichopoulos D
    Cancer Res; 2006 Feb; 66(4):2468-75. PubMed ID: 16489054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study.
    Wedrén S; Lovmar L; Humphreys K; Magnusson C; Melhus H; Syvänen AC; Kindmark A; Landegren U; Fermér ML; Stiger F; Persson I; Baron J; Weiderpass E
    Breast Cancer Res; 2004; 6(4):R437-49. PubMed ID: 15217512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.